Endothelin receptor antagonists in pulmonary arterial hypertension

Journal of the American College of Cardiology

Volumn 43, Issue 12 SUPPL., 2004, Pages S62-S67

  Channick, Richard N ^a,e   Sitbon, Olivier ^b   Barst, Robyn J ^c   Manes, Alessandra ^d   Rubin, Lewis J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c New York Presbyterian Hospital Columbia University Medical Center   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UCSD MEDICAL CENTER   (United States)

Author keywords

6 min walk test; 6MWT; chronic thromboembolic pulmonary hypertension; CTEPH; endothelin; endothelin receptor A; endothelin receptor antagonists; endothelin receptor B; ERAs; ET; ET B; ETA; idiopathic pulmonary arterial hypertension; IPAH; PAH

Indexed keywords

AMBRISENTAN; ANTICOAGULANT AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CONTRACEPTIVE AGENT; CYCLOSPORIN A; DIGOXIN; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; GLIBENCLAMIDE; HEMOGLOBIN; HORMONE; PLACEBO; PROSTACYCLIN; PROSTANOID; SILDENAFIL; SITAXSENTAN; UNIPROST; WARFARIN;

CLINICAL CHEMISTRY; CONFERENCE PAPER; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; EDEMA; EXERCISE; FLUSHING; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEALTH STATUS; HEMODYNAMICS; HEMOGLOBIN DETERMINATION; HEPATITIS; HUMAN; LABORATORY TEST; LIVER DISEASE; LIVER FUNCTION; LIVER INJURY; LONG TERM CARE; NAUSEA; NONHUMAN; NOSE CONGESTION; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTHROMBIN TIME; PULMONARY HYPERTENSION; RANDOMIZATION; SCLERODERMA; SIDE EFFECT; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 2942511669     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.02.042     Document Type: Conference Paper

References (38)

1. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415
2. Yoshimoto S., Ishizaki Y., Sasaki T., Murota S. Effect of carbon dioxide and oxygen on endothelin production by cultured porcine cerebral endothelial cells. Stroke. 22:1991;378-383
3. Takuwa Y., Kasuya Y., Takuwa N., et al. Endothelin receptor is coupled to phospholipase C via pertussis toxin insensitive guanine nucleotide binding regulatory protein in vascular smooth muscle cells. J Clin Invest. 85:1990;653-658
4. Benigni A. Defining the role of endothelins in renal pathophysiology on the basis of selective and unselective endothelin receptor antagonist studies. Curr Opin Nephrol Hypertens. 4:1995;349-353
5. Masaki T. The discovery of endothelins. Cardiovasc Res. 39:1998;530-533
6. 2+ channel blocker LOE 908. Br J Pharmacol. 126:1999;1107-1114
7. Clarke J., Benjamin N., Larkin W., Webb D.J., Davies G.J., Maseri A. Endothelin is a potent long lasting vasoconstrictor in men. Am J Physiol. 257:1989;H2033-H2035
8. Chua B., Krebs C.T., Chua C.C., Diglio C.A. Endothelin stimulates protein synthesis in smooth muscle cells. Am J Physiol. 262:1992;E412-E416
9. B receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med. 165:2002;398-405
10. Sugawara F., Ninomiya H., Okamoto Y., et al. Endothelin-1-induced mitogenic responses of Chinese hamster ovary cells expressing human endothelin A The role of a wortmannin-sensitive signalling pathway. Molec Pharmacol. 49:1996;447-457
11. Sakurai T., et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 348:1990;732-735
12. Hirata Y., Emori T., Eguchi S. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest. 91:1993;1367-1373
13. de Nucci G., Thomas R., D Orleans-Juste P., et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A. 85:1988;9797-9800
14. Filep J., Herman F., Battstini B., Chabrier P.E., Braquet P., Sirois P. Antiaggregatory and hypotensive effects of endothelin-1 in beagle dogs Role for prostacyclin. J Cardiovasc Pharmacol. 17:(Suppl 7):1991;S216-S218
15. Masaki T. Possible role of endothelin in endothelial regulation of vascular tone. Ann Rev Pharmacol Toxicol. 35:1995;235-255
16. B receptor in the regulation of pulmonary vascular tone. Pulm Pharmacol Ther. 13:2000;135-140
17. Kuc R., Davenport A. Endothelin-A receptors in human aorta and pulmonary arteries are downregulated in patients with cardiovascular disease An adaptive response to increased levels of endothelin-1? J Cardiovasc Pharmacol. 36:(Suppl 1):2000;S377-S379
18. Stewart D.J., Levy R.D., Cernacek P., Langleben D. Increased plasma endothelin-1 in pulmonary hypertension Marker or mediator of disease? Ann Intern Med. 114:1991;464-469
19. Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 328:1993;1732-1739
20. Giaid A. Nitric oxide and endothelin-1 in pulmonary hypertension. Chest. 114:1998;S208-S212
21. Bando K., Vijayaraghavan P., Turrentine M.W., et al. Dynamic changes of endothelin-1, nitric oxide, and cyclic GMP in patients with congenital heart disease. Circulation. 96:(Suppl II):1997;II346-II351
22. Ishikawa S., Miyauchi T., Sakai S., et al. Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair. J Thorac Cardiovasc Surg. 110:1995;271-273
23. Lutz J., Golenflo M., Habighorst M., Vogel M., Lange P.E., Hocher B. Endothelin-1 and endothelin receptors in lung biopsies of patients with pulmonary hypertension due to congenital-heart disease. Clin Chem Lab Med. 37:1999;423-428
24. Kim H., Yung G.L., Marsh J.J., et al. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Eur Respir J. 15:2000;640-648
25. Kim H., Yung G.L., Marsh J.J., et al. Pulmonary vascular remodeling distal to pulmonary artery ligation is accompanied by upregulation of endothelin receptors and nitric oxide synthase. Exp Lung Res. 26:2000;287-301
26. Bauer M., Wikens H., Langer F., Schneider S.O., Lausberg H., Schafers H.J. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation. 105:2002;1034-1036
27. Channick R., Sunomeau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension A randomized placebo controlled study. Lancet. 358:2001;1119-1123
28. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 346:2002;896-903
29. Galie N., Hinderliter A.L., Torbicki A., et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 41:2003;1380-1386
30. Sitbon O., Badesch D.B., Channick R.N., et al. Effects of the dual endothelin antagonist bosentan in patients with pulmonary arterial hypertension A 1-year follow-up study. Chest. 124:2003;247-254
31. McLaughlin V., Sitbon O., Rubin L.J., et al. The effect of first-line bosentan on survival of patients with primary pulmonary hypertension (abstr). Am J Respir Crit Care Med. 167:2003;A442
32. Fattinger K., Funk C., Pantze M., et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump A potential mechanism for hepatic adverse reactions. Clin. Pharmacol Ther. 69:2001;223-231
33. Coceani F., Kelsey L. Endothelin-1 release from lamb ductus arteriosus Relevance to postnatal closure of the vessel. Can J Physiol Pharmacol. 69:1991;218-221
34. Kurihara Y., Kurihara H., Suzuki H., et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature. 368:1994;703-710
35. Weber C., Banken L., Birnboeck H., Schulz R. Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol. 39:1999;847-854
36. Humbert M., Barst R.J., Robbins I.M., et al. Safety and efficacy of bosentan combined with epoprostenol in patients with severe pulmonary arterial hypertension (abstr). Am J Respir Crit Care Med. 167:2003;A441
37. Barst R.J., et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Repir Crit Care Med. 169:2004;441-447
38. Barst R., Rich S., Widlitz A., Horn E.M., McLaughlin V., McFarlin J. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension Open-label pilot study. Chest. 121:2002;1860-1868